Böhm M, Beuckelmann D, Brown L, Feiler G, Lorenz B, Näbauer M, Kemkes B, Erdmann E
Medizinische Klinik I, Universität München, F.R.G.
Eur Heart J. 1988 Aug;9(8):844-52. doi: 10.1093/oxfordjournals.eurheartj.a062577.
Cardiac beta-adrenoceptors and the positive inotropic effects of adenylate cyclase-dependent (dobutamine, histamine, forskolin) and adenylate cyclase-independent agents (isobutylmethylxanthine (IBMX), dibutyryl-cAMP (db-cAMP), digoxin, digitoxin and calcium were measured in papillary muscle strips from severely failing (NYHA IV), moderately failing (NYHA II-III) and non-failing (NYHA I) human hearts. The density of beta-adrenoceptors in three NYHA I patients were 40.0, 42.0 and 42.9 fmol mg-1 protein. The density of cardiac beta-adrenoceptors was significantly reduced in NYHA II-III to 18.0 +/- 1.1 fmol mg-1 protein (n = 16) and further reduced in NYHA IV to 9.5 +/- 1.6 fmol mg-1 protein (n = 7). The KD values did not differ between the groups. Correspondingly, the positive inotropic effect of dobutamine was significantly reduced in NYHA II-III and almost lost in NYHA IV. The positive inotropic effect of histamine was similar in non-failing and moderately failing myocardium but reduced in preparations from severely failing hearts (NYHA IV). The positive inotropic effect of IBMX was diminished in moderately and severely failing myocardium depending on the functional class of heart failure. In contrast, the effects of forskolin, db-cAMP, digoxin and digitoxin were not impaired in NYHA IV when compared with the maximal positive inotropic effect of calcium. It is concluded that in the failing human heart (a) the number of cardiac beta-adrenoceptors is reduced proportional to the severity of heart failure; (b) the receptor coupling of H2-receptors to adenylate cyclase may be impaired, but only in severe heart failure; (c) the basal cAMP formation may be diminished; and that (d) the catalytic subunit of the adenylate cyclase and the cAMP-dependent protein kinases may be promising targets for drugs to restore force of contraction in human heart failure.
在严重衰竭(纽约心脏协会IV级)、中度衰竭(纽约心脏协会II - III级)和未衰竭(纽约心脏协会I级)的人类心脏乳头肌条中,测量了心脏β - 肾上腺素能受体以及腺苷酸环化酶依赖性药物(多巴酚丁胺、组胺、福斯高林)和腺苷酸环化酶非依赖性药物(异丁基甲基黄嘌呤(IBMX)、二丁酰环磷腺苷(db - cAMP)、地高辛、洋地黄毒苷和钙)的正性肌力作用。三位纽约心脏协会I级患者的β - 肾上腺素能受体密度分别为40.0、42.0和42.9 fmol mg⁻¹蛋白质。纽约心脏协会II - III级患者心脏β - 肾上腺素能受体密度显著降低至18.0±1.1 fmol mg⁻¹蛋白质(n = 16),纽约心脏协会IV级患者进一步降低至9.5±1.6 fmol mg⁻¹蛋白质(n = 7)。各实验组的解离常数(KD值)无差异。相应地,多巴酚丁胺的正性肌力作用在纽约心脏协会II - III级患者中显著降低,在纽约心脏协会IV级患者中几乎消失。组胺在未衰竭和中度衰竭心肌中的正性肌力作用相似,但在严重衰竭心脏(纽约心脏协会IV级)的标本中降低。IBMX的正性肌力作用在中度和重度衰竭心肌中减弱,这取决于心力衰竭的功能分级。相比之下,与钙的最大正性肌力作用相比,福斯高林、db - cAMP、地高辛和洋地黄毒苷在纽约心脏协会IV级患者中的作用未受损。得出的结论是,在衰竭的人类心脏中:(a)心脏β - 肾上腺素能受体数量的减少与心力衰竭的严重程度成正比;(b)H2受体与腺苷酸环化酶的受体偶联可能受损,但仅在严重心力衰竭时;(c)基础环磷腺苷(cAMP)的生成可能减少;以及(d)腺苷酸环化酶的催化亚基和cAMP依赖性蛋白激酶可能是恢复人类心力衰竭收缩力的药物的有前景的靶点。